Medication info
Seviduo Tablets 5/40 mg

Seviduo Tablets 5/40 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
Alu-Alu - 30 tablets/Alu-Alu[(10 tablets/Alu-Alu X 3)]
Approval status
Active

MFDS item code 201404822 · Approved 2014.10.21 · Insurance code 645404290

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medication be taken at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medication. However, switching directly to this medication may be considered if blood pressure is not controlled with monotherapy with an individual component. The maximum dose of this medication is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medication must not be administered under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Essential hypertension
View approved original text

This medicine is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure cannot be adequately controlled by monotherapy with amlodipine or olmesartan medoxomil, thereby treating hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medication be taken at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before starting this medication. However, switching directly to this medication may be considered if blood pressure is not controlled with monotherapy with an individual component. The maximum dose of this medication is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medication must not be administered under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Do not take this medicine if you have an allergy to any of the ingredients, are pregnant, or are breastfeeding. Patients with severely impaired liver or kidney function, severe aortic stenosis, biliary obstruction, patients undergoing renal dialysis, patients in shock, or patients with certain types of diabetes should not take this medicine. Patients with genetic issues such as lactose intolerance should also not take this medicine. Careful monitoring of low blood pressure symptoms is needed when starting this medication in patients with low fluid or salt levels. The medicine may cause vasodilation leading to hypotension, particularly in patients with severe aortic stenosis. Patients with severe coronary artery disease or congestive heart failure may experience worsening of their heart condition, so caution is advised while taking this medicine. Patients with reduced kidney function may have an increased risk of further deterioration of kidney function while taking this medicine. For patients with impaired liver function, metabolism of this medicine may be slowed, therefore caution should be taken when administering. This medicine may cause various side effects including dizziness, headache, hypotension, edema, indigestion, skin rash, etc., so if symptoms are severe, consult a healthcare professional. Pregnant or breastfeeding women should avoid taking this medicine due to risks to the fetus or infant, or consult a doctor. This medicine is not recommended for children under 18 as its safety and efficacy have not been established. Elderly patients should carefully adjust the dosage considering the possibility of reduced kidney and liver function. In case of overdose, severe hypotension, vasodilation, tachycardia, etc. may occur, and immediate medical attention is needed. This medicine should be stored in a closed container away from moisture, heat, and direct sunlight, out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypoesthesia
  • syncope
Show 82 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • lumbago
  • pollakiuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • elevated gamma-glutamyl transferase
  • decrease in hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute kidney injury
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • elevated liver enzymes
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a closed container to protect it from air and moisture. Additionally, it is recommended to store the medicine at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

Alu-Alu - 30 tablets/Alu-Alu[(10 tablets/Alu-Alu X 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.